CRISPR THERAPEUTICS AG (CRSP) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $3.13M; Additional Paid in Capital, Common StockUSD $3.91B; Treasury Stock, ValueCHF (m); Treasury Stock, ValueUSD $60.00K.
- 2026-03-31: Common Stock, Value, IssuedUSD $3.12M; Additional Paid in Capital, Common StockUSD $3.88B; Treasury Stock, ValueCHF (m); Treasury Stock, ValueUSD $60.00K.
- 2025-12-31: Common Stock, Value, IssuedUSD $3.09M; Additional Paid in Capital, Common StockUSD $3.86B; Treasury Stock, ValueCHF (m); Treasury Stock, ValueUSD $60.00K.
- 2025-09-30: Common Stock, Value, IssuedUSD $3.01M; Additional Paid in Capital, Common StockUSD $3.72B; Treasury Stock, ValueCHF (m); Treasury Stock, ValueUSD $60.00K.
CRISPR THERAPEUTICS AG Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Value CHF | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Value, Acquired, Cost Method USD | Treasury Stock, Shares, Acquired shares | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.13M | $3.91B | (m) | $60.00K | $-4.63M | $-2.16B | $1.75B | 100.32K | 3 month · $17.32M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $3.12M | $3.88B | (m) | $60.00K | $-1.94M | $-2.07B | $1.81B | 115.32K | 3 month · $16.32M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $3.09M | $3.86B | (m) | $60.00K | $4.82M | $-1.95B | $1.92B | 115.32K | 12 month · $72.50M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $3.01M | $3.72B | (m) | $60.00K | $4.99M | $-1.82B | $1.92B | 125.32K | 3 month · $16.60M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $2.79M | $3.41B | (m) | $62.00K | $4.04M | $-1.71B | $1.71B | 170.32K | 3 month · $17.61M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $2.72M | $3.32B | (m) | $62.00K | $4.13M | $-1.50B | $1.83B | 170.32K | 3 month · $20.21M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $2.70M | $3.29B | (m) | $62.00K | $1.84M | $-1.37B | $1.93B | 170.32K | 12 month · $86.57M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $2.68M | $3.26B | (m) | $62.00K | $10.56M | $-1.33B | $1.94B | 170.32K | 3 month · $21.54M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $2.67M | $3.22B | (m) | $62.00K | $-2.88M | $-1.24B | $1.98B | 170.32K | 3 month · $23.67M | (m) | (m) | (m) | (m) |
| 2024-03-31 | $2.66M | $3.20B | (m) | $62.00K | $-1.55M | $-1.12B | $2.08B | 170.32K | 3 month · $19.41M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $2.50M | $2.88B | (m) | $62.00K | $1.91M | $-999.70M | $1.88B | 170.32K | 12 month · $81.03M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $2.48M | $2.82B | (m) | $63.00K | $-6.80M | $-1.09B | $1.73B | 180.32K | 3 month · $19.97M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $2.47M | $2.80B | (m) | $63.00K | $-8.91M | $-976.89M | $1.82B | 180.32K | 3 month · $21.77M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $2.45M | $2.76B | (m) | $63.00K | $-9.39M | $-899.15M | $1.85B | (m) | 3 month · $20.88M | (m) | (m) | (m) | 180.32K |
| 2022-12-31 | $2.44M | $2.73B | (m) | $63.00K | $-15.65M | $-846.09M | $1.88B | 180.32K | 12 month · $97.95M | (m) | (m) | (m) | 180.32K |
| 2022-09-30 | $2.43M | $2.71B | (m) | $63.00K | $-22.26M | $-735.51M | $1.95B | (m) | 3 month · $24.54M | (m) | (m) | (m) | 180.32K |
| 2022-06-30 | $2.42M | $2.67B | (m) | $63.00K | $-20.34M | $-560.97M | $2.09B | (m) | 3 month · $24.85M | (m) | (m) | (m) | 180.32K |
| 2022-03-31 | $2.41M | $2.63B | (m) | $63.00K | $-16.89M | $-375.13M | $2.24B | (m) | 3 month · $25.75M | (m) | (m) | (m) | 180.32K |
| 2021-12-31 | $2.39M | $2.60B | (m) | $63.00K | $-5.07M | $-195.91M | $2.40B | (m) | 12 month · $102.39M | (m) | (m) | (m) | 180.32K |
| 2021-09-30 | $2.37M | $2.57B | (m) | $63.00K | $-770.00K | $-54.67M | $2.51B | (m) | 3 month · $26.20M | (m) | (m) | (m) | 180.32K |
| 2021-06-30 | $2.35M | $2.53B | (m) | $63.00K | $-629.00K | $72.49M | $2.60B | (m) | 3 month · $28.33M | (m) | (m) | (m) | 195.32K |
| 2021-03-31 | $2.34M | $2.49B | (m) | $63.00K | $-461.00K | $-686.74M | $1.81B | (m) | 3 month · $22.09M | (m) | (m) | (m) | 195.32K |
| 2020-12-31 | $2.28M | $2.24B | (m) | $63.00K | $-83.00K | $-573.58M | $1.66B | (m) | 12 month · $66.02M | (m) | (m) | (m) | 195.32K |
| 2020-09-30 | $2.16M | $1.81B | (m) | $63.00K | $-134.00K | $-466.54M | $1.34B | (m) | 3 month · $17.24M | (m) | (m) | (m) | 195.32K |
| 2020-06-30 | $1.90M | $1.28B | (m) | $63.00K | $-21.00K | $-374.10M | $910.67M | (m) | 3 month · $15.70M | (m) | (m) | (m) | 195.32K |
| 2020-03-31 | $1.85M | $1.18B | (m) | $63.00K | $-18.00K | $-294.44M | $886.10M | (m) | 3 month · $14.15M | (m) | (m) | (m) | 232.40K |
| 2019-12-31 | $1.85M | $1.16B | (m) | $63.00K | $7.00K | $-224.71M | $939.42M | (m) | 12 month · $49.52M | (m) | (m) | (m) | 250.23K |
| 2019-09-30 | $1.68M | $845.53M | (m) | $57.00K | $-22.00K | $-255.25M | $591.88M | (m) | 3 month · $14.77M | (m) | (m) | (m) | 256.99K |
| 2019-06-30 | $1.63M | $759.80M | (m) | $57.00K | $-10.00K | $-393.68M | $367.68M | (m) | 3 month · $12.20M | (m) | (m) | (m) | 256.99K |
| 2019-03-31 | $1.59M | $718.25M | (m) | $57.00K | (m) | $-339.98M | $379.81M | (m) | 3 month · $10.70M | (m) | (m) | (m) | 307.94K |
| 2018-12-31 | $1.58M | $682.25M | (m) | $57.00K | $-8.00K | $-291.57M | $392.19M | (m) | 12 month · $39.26M | $392.19M | 12 month · $57.00K | (m) | 307.94K |
| 2018-09-30 | $1.57M | $659.78M | (m) | $57.00K | $-1.00K | $-243.98M | $417.31M | (m) | 3 month · $9.07M | (m) | 3 month · $7.00K | (m) | 307.94K |
| 2018-06-30 | $1.44M | $457.03M | (m) | $50.00K | $5.00K | $-193.27M | $265.15M | (m) | 3 month · $9.48M | (m) | (m) | (m) | 409.36K |
| 2018-03-31 | $1.42M | $443.77M | (m) | $0.00 | $26.00K | $-154.89M | $290.33M | (m) | 3 month · $6.67M | (m) | (m) | (m) | 438.62K |
| 2017-12-31 | $1.24M | $312.02M | (m) | $0.00 | $14.00K | $-125.44M | $187.83M | (m) | 12 month · $20.64M | $187.83M | (m) | (m) | 444.87K |
| 2017-09-30 | $1.23M | $303.29M | (m) | $0.00 | $12.00K | $-125.58M | $178.96M | (m) | (m) | (m) | (m) | (m) | 444.87K |
| 2017-06-30 | $1.23M | $297.45M | (m) | $0.00 | $4.00K | $-100.87M | $197.80M | (m) | (m) | (m) | (m) | (m) | 444.87K |
| 2017-03-31 | $1.22M | $292.52M | (m) | $0.00 | $-2.00K | $-78.56M | $215.18M | (m) | (m) | (m) | (m) | (m) | 444.87K |
| 2016-12-31 | $1.22M | $288.74M | (m) | $0.00 | $-26.00K | $-57.08M | $232.85M | (m) | 12 month · $10.84M | $232.85M | (m) | (m) | 0.00 |
| 2016-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | 170.69K | (m) |
| 2016-09-30 | $174.00K | $11.55M | 0.00 | $0.00 | $-26.00K | $-74.18M | $-62.48M | (m) | (m) | $-62.53M | (m) | (m) | 274.18K |
| 2015-12-31 | $181.00K | $4.64M | 0.00 | $0.00 | $-8.00K | $-33.91M | $-29.10M | (m) | 12 month · $3.68M | $-29.12M | (m) | (m) | 0.00 |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $695.00K | $-6.97M | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-581.00K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |